Anti-Crk-like protein CrkL Antibody Picoband® Fluoro647 Conjugated

CRKL (v-crk sarcoma virus CT10 oncogene homolog (avian) -like) also called ONCOGENE  CRKL, encodes a 303-amino acid polypeptide with a predicted molecular mass of 36 kD. While  CRKL  is not the human homolog of CRK, it is similar to protein-tyrosine kinases with SH2 and SH3 (src homology) domains. By fluorescence in situ hybridization,   the  CRKL  gene is localized to chromosome 22q11, centromeric of the chronic myelogenous leukemia breakpoint region. Senechal et al. (1996)   showed that  CRKL  becomes phosphorylated when overexpressed, activates Ras-dependent and JNK pathways, and transforms fibroblasts. The authors also found  CRKL  to be a substrate for the BCR-ABL tyrosine kinase, leading them to conclude thatCRKL  is a tyrosine kinase and an oncogene. Crkl  was required for normal cellular responses to Fgf8, including survival and migration, Erk activation, and target gene expression.

1. Guris, D. L., Duester, G., Papaioannou, V. E., Imamoto, A. Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome. Dev. Cell 10: 81-92, 2006. 2. Moon, A. M., Guris, D. L., Seo, J., Li, L., Hammond, J., Talbot, A., Imamoto, A. Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. Dev. Cell 10: 71-80, 2006. 3. Senechal, K., Halpern, J., Sawyers, C. L. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J. Biol. Chem. 38: 23255-23261, 1996.